Kobe University · University Hospital · 助教

Research keywords転移性腎細胞癌・前立腺癌・去勢抵抗性前立腺癌・Hinotoriロボット手術・ロボット支援前立腺全摘除術・ロボット支援腎部分切除術・アパルタミド皮疹・腎癌下大静脈腫瘍塞栓・副腎褐色細胞腫・尿路上皮癌免疫療法

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Extraperitoneal Robot-Assisted Radical Prostatectomy Using Hinotori™ Surgical Robot System: Report of First Series of Seven Cases.2025 · OBJECTIVES: The Hinotori™ surgical robot system (HSRS) (Medicaroid, Kobe, Japan), a newly launched domestic platform in Japan, has already been utilized in many robot-assisted surgeries. This study aimed to assess the perioperative outcomes of the first series of seven cases that underwent robot-assisted radical prostatectomy (RARP) with an extraperitoneal approach (EP) using HSRS. METHODS: A total of seven consecutive patients with localized prostate cancer who underwent RARP with EP using the HSRS between January and May 2025 at our institution were included in this study. Their comprehensive perioperative outcomes were retrospectively analyzed. RESULTS: The median age and the body mass index (BMI) of the patients were 69 years and 21.9 kg/m², respectively. RARP with EP could be completely performed on all patients without conversion to either a transperitoneal approach or open surgery. The median operative time, the time using the robotic system, the estimated blood loss, and the length of the indwelling urethral catheter were 180 min, 96 min, 100 mL, and seven days, respectively. No patient experienced major perioperative complications requiring invasive treatment or blood transfusion. CONCLUSIONS: Despite being a small case series, this is the first report of the perioperative finding that RARP with EP using the HSRS is expected to provide equivalent perioperative outcomes compared to RARP with transperitoneal (TP).
• Comparative prognostic value of tumor volume in IOIO and IOTKI treatment for metastatic renal cancer2025 · Elsevier BV, 2025年01月, Urologic Oncology: Seminars and Original Investigations, 43(1) (1), 63.e19 - 63.e27
• 転移性去勢抵抗性前立腺癌に対するアパルタミドの有効性と安全性 前向き多施設研究2025 · (一社)日本癌治療学会, 2025年10月, 日本癌治療学会学術集会抄録集, 63回, FR3 - 4, 英語
• Dose Per Body Weight Predicts Incidence and Severity of Apalutamide-Related Skin Rash in Metastatic Castration-Sensitive Prostate Cancer2025 · 2025年02月, Clinical Genitourinary Cancer

• 腎細胞癌におけるＡｕｒｏｒａ－Ａの役割の解明および新規治療の開発 寺川 智章 学術研究助成基金助成金／若手研究(B), 2011年, 研究代表者 競争的資金2011 · KUID parsed section
• 前立腺癌のホルモン非依存性進展におけるＩｎｔｅｒｌｅｕｋｉｎ‐６の役割の解明 寺川 智章 科学研究費補助金／若手研究(B), 2010年, 研究代表者 競争的資金2010 · KUID parsed section
• 腎細胞癌におけるＡｕｒｏｒａ－Ａの役割の解明および新規治療の開発
• 前立腺癌のホルモン非依存性進展におけるＩｎｔｅｒｌｅｕｋｉｎ‐６の役割の解明

• Official profile
• ORCID